期刊文献+

磁性氟尿嘧啶白蛋白微球抗人胰腺癌的实验研究 被引量:2

Inhibitory effects of 5-fluorouracil magnetic albumin microsphere on human pancreatic carcinoma
原文传递
导出
摘要 目的研究磁性氟尿嘧啶白蛋白微球(5-fluorouracil magnetic albumin microspheres,5-FU-MAMS)联合恒定外磁场体内外对人胰腺癌的生长抑制作用。方法体外培养人胰腺癌PC-3细胞及建立裸鼠人胰腺癌模型,磁场作用下,观察5-FU—MAMS体内外对人胰腺癌的生长抑制作用。结果5-FU-MAMS在外加磁场的磁导向作用下,体外5-FU-MAMS能显著抑制肿瘤细胞生长,与其它组比较,抑制率(IR)明显提高(P〈0.05);体内5-FU—MAMS能很好的定位于肿瘤组织并显著抑制肿瘤生长,肿瘤体积抑制率达到90.47%,肿瘤重量抑制率达到88.16%,与其它组比较,差异有统计学意义(P〈0.01)。结论在磁场作用下,5-FU—MAMS作为靶向药物治疗胰腺癌能够取得良好的效果。 Objective To investigate the inhibiting effects of 5 fluorouracil magnetic albumin microsphere (5-FU-MAMS) in combination with constant external magnetic fields on human pancreat ic carcinoma in vitro and in vivo. Methods The human pancreatic carcinoma PC 3 cells were cultured and an experimental model was established in nude mice to investigate the inhibiting effects. Results In vitro study showed that 5-FU-MAMS in combination with constant external magnetic fields could significantly inhibit the growth of PC 3 cells as compared with other agents (P〈0.05). The in vivo study revealed that 5-FU-MAMS could be well localized in the tumor tissue and markedly inhibit the growth of tumor. The inhibitory rate of tumor size was 90. 47% and that of tumor weight 88. 16%. There were significant differences as compared with other groups (P〈0.05). Conclusion Under constant external magnetic fields, 5-FU-MAMS can achieve satisfactory results for targeted therapy of pancreatic carcinoma.
出处 《中华肝胆外科杂志》 CAS CSCD 2008年第10期739-741,共3页 Chinese Journal of Hepatobiliary Surgery
基金 贵州省优秀科技教育人才省长专项基金资助项目[基金号:黔科教办(2001)3号]
关键词 胰腺肿瘤 磁性5-氟尿嘧啶蛋白微球 靶向治疗 Pancreatic neoplasms 5-FU-MAMS Targeted therapy
  • 相关文献

参考文献7

  • 1Hioki Y, Masaji T, Hironobu O, et al. Locoregional chemotherapy for patients with pancreatic cancer intr arterial adjuvant chemotherapy after pancreatectomy with portal vein reseac tion. Pancreas, 2002,25 : 366-372.
  • 2Hawes RH, Xiong Q, Waxman I, et al. A multispeciality approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol, 2000,95 : 17.
  • 3Brigger I, Dubernet C, Couvreur P. Nanopartcles in cancer therapy and diagnosis. Adv Drug Deliv Rev, 2002, 54:631-651.
  • 4Hafeli UO,Pauer GJ. In vitro and in vivo toxicity of magnetic microspheres. J Magn Magn Mater, 1999,194 :76-82.
  • 5Senyei AE,Reich SD,Gonczy C,et al. In vivo kinetics of magnetically targeted low dose doxorubicin. Pharm Sci, 1981,70: 389.
  • 6Andreas SL,Christoph A,Christian B. Clinnical applications of magnetic targeting. J Surg Res,2000,95:200 206.
  • 7Singhal S,Mehta J,Desikan R,et al. Antitumor activity of thalidomide in refractory multiple myeloma, N Engl J Med, 1999, 341 : 1565-1571.

同被引文献10

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部